200
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase

, , , , , , , , , , , , , , , , & show all
Pages 1851-1858 | Received 05 Apr 2016, Accepted 28 Jul 2016, Published online: 18 Aug 2016
 

ABSTRACT

Objective: Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). This study was the first prospective evaluation of the efficacy and safety of nilotinib in Turkish patients with newly diagnosed CML-CP. The primary endpoint of the study was the rate of major molecular response (MMR; BCR-ABL1 ≤ 0.1% on the International Scale [BCR-ABL1IS]) by 12 months.

Methods: Patients with newly diagnosed CML-CP were treated with nilotinib 300 mg twice daily. This analysis was based on the first 12 months of follow-up in a 24-month study.

Results and Conclusions: Of 112 patients enrolled, 66.1% (80% CI, 59.7–72.0%) achieved MMR and 22.3% achieved a deep molecular response of MR4.5 (BCR-ABL1IS ≤ 0.0032%) by 12 months. During the first year of treatment, 1 patient progressed to blast crisis and 2 patients died. Safety results were consistent with previous studies. Most adverse events (AEs) were grade 1/2. Most frequently reported nonhematologic AEs of any grade were elevations in bilirubin, alanine aminotransferase, and triglycerides. These results support the use of nilotinib 300 mg twice daily as a standard-of-care treatment option for patients with newly diagnosed CML-CP.

Declaration of interest

In collaboration with the study investigators, the study sponsor (Novartis Pharmaceuticals Corporation) participated in the design of the study and the data analyses and interpretation.

G Saydam has received honoraria from Novartis, Celgene, Bristol-Myers Squibb, and Gilead; served on speakers bureaus for Novartis and Bristol-Myers Squibb, and served as a consultant for Novartis. IC Haznedaroglu has received research funding from, and served on advisory committees for, Novartis. AS Yavuz has served on advisory committees for Novartis. DZ Akkaynak and IM Dag are employees of Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Writing assistance was utilised in the preparation of this manuscript; it was funded by Novartis and carried out by Karen Kaluza, PhD, and Joy Loh, PhD (both of ArticulateScience LLC).

Additional information

Funding

This study was funded by Novartis Pharmaceuticals Corporation.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 884.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.